Corrigendum to “Wogonin Inhibits Cardiac Hypertrophy by Activating Nrf-2-Mediated Antioxidant Responses”

---

X. Shi, B. Zhang, Z. Chu, et al., “Wogonin Inhibits Cardiac Hypertrophy by Activating Nrf-2-Mediated Antioxidant Responses”, Cardiovascular Therapeutics 2021 (2021): 9995342, https://doi.org/10.1155/2021/9995342

In the article, there is an error in Figure 4e due to the incorrect selection of images during manuscript preparation. The correct Figure 4 is shown below:

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

Figure 4 

Wog prevented TAC-induced cardiac hypertrophy and dysfunction in vivo. (a, b) Echocardiographic data showed the effects of Wog on cardiac hypertrophy induced by TAC. EF: ejection fraction; FS: fractional shortening (); (c) representative M-mode echocardiograms from sham and TAC mice with vehicle or Wog; (d–f) histological staining of H&E and WGA of heart sections showed the inhibitory effect of Wog on cardiac hypertrophy after TAC surgery (magnification: ×200, scale bar: 20 μm). Quantitative analysis of cardiomyocyte cross-sectional area (); (g) representative hearts of mice that underwent sham or TAC surgery, followed by single intragastric administration of Wog (10 mg/kg/day) for 8 weeks; (h) quantitative analysis of the heart weight/body weight (HW/BW) ratio (); (i–k) mRNA expressions for Anp, Bnp, and Myhc-β determined by qRT-PCR (). , , and compared to sham; ^#, ^##, and ^### compared to TAC.

The authors apologize for this error.